ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022
Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Radioligand therapy for pediatric patients with solid tumors.The British journal of radiology · 2026Review
- First-in-Human, Open-label, Single-Arm Phase I Study of [211At] meta-Astatobenzylguanidine in Patients with Pheochromocytoma or Paraganglioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- An integrative multi-omics landscape of multi-dimensional cellular stress and metabolic reprogramming in melanoma treated with targeted alpha therapy.Journal of nanobiotechnology · 2026Article
- Influence of Subcellular Localization on the Cytotoxicity of Targeted α-Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Clinical applications and future directions of Iodine-131-Metaiodobenzylguanidine therapy in neuroblastoma: from salvage treatment to frontline integration.Annals of nuclear medicine · 2026Review
- Astatine-211-Towards In Vivo Stable Astatine-211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications.Medicinal research reviews · 2026Review
- Theranostic Application of Radiohalogens in Nuclear Medicine.Nuclear medicine and molecular imaging · 2025Review
- LAT1-Targeted Alpha Therapy UsingInternational journal of molecular sciences · 2025Article
- Fibroblast activation protein targeting radiopharmaceuticals: From drug design to clinical translation.Acta pharmaceutica Sinica. B · 2025Review
- Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work Better.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Copper-mediated radiochemistry: historical impact, current trends, and future possibilities.Npj imaging · 2025Review
- Astatine-211 and actinium-225: two promising nuclides in targeted alpha therapy.Acta biochimica et biophysica Sinica · 2024Review
- Recent advances in spatio-temporally controllable systems for management of glioma.Asian journal of pharmaceutical sciences · 2024Review
- Recent advances in the development ofAnalytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024Review
- Navigating new horizons: Prospects of NET-targeted radiopharmaceuticals in precision medicine.Theranostics · 2024Review
- Effective Treatment of SSTR2-Positive Small Cell Lung Cancer UsingMolecular pharmaceutics · 2023Article
- ACell reports. Medicine · 2023Article
- Astatine-211 based radionuclide therapy: Current clinical trial landscape.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
Abstract
purpose[131I]meta-iodobenzylguanidine ([131I]MIBG) is a targeted radiotherapeutic administered systemically to deliver beta particle radiation in neuroblastoma. However, relapses in the bone marrow are common. [211At]meta-astatobenzylguanidine ([211At] MABG) is an alpha particle emitter with higher biological effectiveness and short path length which effectively sterilizes microscopic residual disease. Here we investigated the safety and antitumor activity [211At]MABG in preclinical models of neuroblastoma. EXPERIMENTAL
designWe defined the maximum tolerated dose (MTD), biodistribution, and toxicity of [211At]MABG in immunodeficient mice in comparison with [131I]MIBG. We compared the antitumor efficacy of [211At]MABG with [131I]MIBG in three murine xenograft models. Finally, we explored the efficacy of [211At]MABG after tail vein xenografting designed to model disseminated neuroblastoma.
resultsThe MTD of [211At]MABG was 66.7 MBq/kg (1.8 mCi/kg) in CB17SC scid-/- mice and 51.8 MBq/kg (1.4 mCi/kg) in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. Biodistribution of [211At]MABG was similar to [131I]MIBG. Long-term toxicity studies on mice administered with doses up to 41.5 MBq/kg (1.12 mCi/kg) showed the radiotherapeutic to be well tolerated. Both 66.7 MBq/kg (1.8 mCi/kg) single dose and fractionated dosing 16.6 MBq/kg/fraction (0.45 mCi/kg) × 4 over 11 days induced marked tumor regression in two of the three models studied. Survival was significantly prolonged for mice treated with 12.9 MBq/kg/fraction (0.35 mCi/kg) × 4 doses over 11 days [211At]MABG in the disseminated disease (IMR-05NET/GFP/LUC) model (P = 0.003) suggesting eradication of microscopic disease.
conclusions[211At]MABG has significant survival advantage in disseminated models of neuroblastoma. An alpha particle emitting radiopharmaceutical may be effective against microscopic disseminated disease, warranting clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.